Patents by Inventor Peter Andreas
Peter Andreas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9127052Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.Type: GrantFiled: June 28, 2011Date of Patent: September 8, 2015Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
-
Patent number: 9127064Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21 F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.Type: GrantFiled: December 15, 2008Date of Patent: September 8, 2015Assignee: Novo Nordisk A/SInventors: Birgitte Urso, Peter Andreas Nicolai Reumert Wagtmann, Inger Lund Pedersen, Anders Svensson
-
Patent number: 9086219Abstract: A regulating device for regulating the course of a gas turbine plant has at least one sensor for sensing a measurement variable and for outputting a measurement signal which represents the measurement variable; at least one adjusting system for influencing air and/or fuel supply to a combustion chamber of the gas turbine plant on the basis of a correcting variable; and a regulator connected to the at least one sensor so as to receive the measurement variable and to the at least one adjusting system for outputting the correcting variable, the regulator being designed to determine the correcting variable on the basis of the measurement variable received and its deviation from a pilot variable. At least one sensor is designed to sense the variation in time of at least one burner or combustion chamber parameter as measurement variable.Type: GrantFiled: May 10, 2006Date of Patent: July 21, 2015Assignee: SIEMENS AKTIENGESELLSCHAFTInventors: Eberhard Deuker, Stefan Pernau, Siegfried Bode, Andreas Diebels, Thomas Hahner, Thomas Hesse, Werner Krebs, Bernd Prade, Peter-Andreas Schneider, Dieter Simon, Berthold Sturm, Heinrich Thölking, Dieter Warnack, Andreas Bauer, Joachim Lepers, Martin Müller
-
Publication number: 20150197569Abstract: A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.Type: ApplicationFiled: January 27, 2015Publication date: July 16, 2015Inventors: Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Rozana Sten, Lene Hjorth Alifrangis, Rune Viig Overgaard
-
Publication number: 20150191547Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: March 16, 2015Publication date: July 9, 2015Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Patent number: 9015945Abstract: A method of forming a flow restriction in a fluid communication system is disclosed. The method comprises the steps of providing a flow restricting section having a cross sectional area and a length, measuring the flow resistivity of the flow restricting section, and modifying the cross sectional area and/or the length of the flow restricting section until a desired flow resistivity of the flow restricting section is obtained. The method provides the possibility of forming a flow restriction in an easy and cost effective manner, and to subsequently adjust the flow resistivity of the flow restriction, thereby obtaining an accurate flow resistivity.Type: GrantFiled: October 7, 2009Date of Patent: April 28, 2015Assignee: Flowsion ApSInventors: Kristian Raaby Poulsen, Peter Andreas Rasmussen
-
Patent number: 9018366Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 18, 2013Date of Patent: April 28, 2015Assignees: Innate Pharma S.A.S, Novo Nordisk A/SInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 8981065Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: July 8, 2013Date of Patent: March 17, 2015Assignees: Novo Nordisk A/S—Novo Alle, Innate Pharma S.A.S., University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Publication number: 20140321486Abstract: The present invention relates to a method and a device for the simultaneous compression and characterization of ultrashort laser pulses. An embodiment of the method comprises applying predetermined spectral phases to the pulse to be characterized so as to perform a dispersion scan; applying a nonlinear process to the pulse to be characterized; measuring the resulting signal from the application of the predetermined spectral phases and nonlinear process; applying a numerical iterative algorithm to the measured signal to retrieve the spectral phase of the pulse to be characterized. A few cycle laser pulse may be negatively chirped with a pair of DCM, the controllable amount of positive dispersion may be provided by a pair of glass wedges, one of them being translated for dispersion or phase control, and the frequency spectrum may be measured as well as also frequency resolved the dispersion dependent second-harmonic of the signal being phase modulated.Type: ApplicationFiled: October 11, 2012Publication date: October 30, 2014Applicant: UNIVERSIDADE DO PORTOInventors: Miguel Nicolau Da Costa Ribeiro De Miranda, Helder Manuel Paiva Rebelo Cerejo Crespo, Thomas Peter Andreas Fordell, Cord Louis Arnold, Anne L'Huillier
-
Publication number: 20140295187Abstract: A composite structure having a number of thermoset resin containing elements and a number of thermoplastic elements and at least one interface between the thermoset resin containing elements and the thermoplastic elements is provided. The thermoset resin containing elements and the thermoplastic elements have functional groups at the interface which bond to each other when the composite structure is cured and the functional groups are independently selected from amines, carboxylic acids, acid anhydrides, oxiranes, and derivatives thereof in their non-bonded condition. Additionally, a blade having such a composite structure is provided.Type: ApplicationFiled: February 16, 2014Publication date: October 2, 2014Applicant: SIEMENS AKTIENGESELLSCHAFTInventors: Peter Andreas Lund Jacobsen, Peter Kybelund
-
Publication number: 20140193430Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: December 13, 2013Publication date: July 10, 2014Applicants: NOVO NORDISK A/S, UNIVERSITY OF GENOA, BRISTOL-MYERS SQUIBB COMPANYInventors: SØREN BERG PADKJAER, ALESSANDRO MORETTA, MARIELLA DELLA CHIESA, PASCALE ANDRE, LAURENT GAUTHIER, PETER ANDREAS NICOLAI RUMERT WAGTMANN
-
Patent number: 8641365Abstract: A rotor of a thermal turbomachine, particularly a gas turbine, is provided. The rotor includes a plurality of individual rotor components that are held together by a tie-bold and combined into a unit. The tie-bolt is supported by the assembly of the surrounding rotor components including the tie-bolt and the rotor disks. A hollow shaft which is made up of two tubular sections and a support wheel further support the rotor.Type: GrantFiled: February 15, 2008Date of Patent: February 4, 2014Assignee: Siemens AktiengesellschaftInventors: Guido Ahaus, Francois Benkler, Ulrich Ehehalt, Harald Hoell, Karsten Kolk, Walter Loch, Harald Nimptsch, Oliver Schneider, Peter-Andreas Schneider, Peter Schröder, Vyacheslav Veitsman
-
Patent number: 8637258Abstract: The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.Type: GrantFiled: June 10, 2010Date of Patent: January 28, 2014Assignees: Novo Nordisk A/S, University of Genoa, Innate Pharma, S.A.Inventors: Soren Berg Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Andreas Nicolai Reumert Wagtmann
-
Publication number: 20140023646Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: ApplicationFiled: October 1, 2013Publication date: January 23, 2014Applicants: Innate Pharma S.A.S., Novo Norkisk A/SInventors: Peter Andreas, Nicolai, Reumert WAGTMANN, Francois ROMAGNE, Joakim GLAMANN
-
Patent number: 8614307Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: January 11, 2012Date of Patent: December 24, 2013Assignees: Novo-Nordisk A/S—Novo Alle, Innate Pharma S.A.S.Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurant Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkjaer, Kristian Kjaergaard, Petrus Johannes Loius Spee, Milchael Wilken
-
Publication number: 20130287770Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: July 8, 2013Publication date: October 31, 2013Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Loius Spee, Milchael Wilken
-
Patent number: 8551483Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: GrantFiled: January 6, 2006Date of Patent: October 8, 2013Assignees: Innate Pharma S.A.S., Novo Nordisk A/SInventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
-
Patent number: 8545171Abstract: A rotor of a thermal fluid flow machine, especially a gas turbine, is provided. The rotor includes a plurality of rotor components that are held together by a common tie-bolt that extends through the center of the rotor components. The tie-bolt is fixed in at least one of the rotor components using at least one star spring that surrounds the tie-bolt in a circumferential direction.Type: GrantFiled: February 15, 2008Date of Patent: October 1, 2013Assignee: Siemens AktiengesellschaftInventors: Francois Benkler, Ulrich Ehehalt, Harald Hoell, Uwe Kahlstorf, Karsten Kolk, Walter Loch, Peter-Andreas Schneider
-
Publication number: 20130206226Abstract: The invention relates to a photovoltaic cell, comprising a plate shaped substrate of a semiconductor material with a solar face and a connection face, a first volume of the substrate adjacent to the solar face is doted with a first polarity, the second volume is doted with a second polarity and the volumes are separated by a pn-junction, a number of apertures in the substrate extending between both faces and in which a plug has been positioned of which a part is conducting, contact tracks at the solar face of the substrate connected with the first volume and the conducting part of the plug, first contacts at the connection face of the substrate connected with the conducting part of the plug and second contacts located at the connection face of the substrate connected with the second volume, wherein the specific electrical conductivity of the plug decreases from its centre to the contact face with the substrate.Type: ApplicationFiled: August 23, 2011Publication date: August 15, 2013Applicant: STICHTING ENERGIEONDERZOEK CENTRUM NEDERLANDInventors: Menno Nicolaas Van Den Donker, Peter Andreas Maria Wijnen
-
Patent number: 8506239Abstract: A gas turbine is provided. The gas turbine includes at least one rotor, having rotor blades arranged on the periphery of rotor disks in a plurality of radial planes, and a tie-bolt extending along slots in the rotor disks and holding the rotor disks together as a unit. At least one annular spacer for fixing the position of the tie-bolt in relation to the center line of the rotor disks is also provided. The spacer includes through-openings that are arranged radially in relation to the tie-bolt or to its center line and that extend coaxially.Type: GrantFiled: February 15, 2008Date of Patent: August 13, 2013Assignee: Siemens AktiengesellschaftInventors: Francois Benkler, Ulrich Ehehalt, Harald Hoell, Walter Loch, Peter-Andreas Schneider